In May 2017, Hemosonics was acquired by the French company Stago Group. HemoSonics, LLC operated as a medical device company developing in vitro diagnostics to quantify and characterize the hemostatic potential of whole blood in clinical settings. Employing a patented approach named sonorheometry (SR) - faster, easier to use, and has a lower cost than competing technologies - the firm's products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy, offering a point-of-care analyzer that characterizes and guides the management of hemostasis disorders. The firm's proncipals developed SR while at the uNversity of Virginia. HemoSonics's products combine a flexible test device with targeted disposable test chambers to diagnose specific defects of hemostasis and inform appropriate therapy. The firm's products have clinical applications in trauma, cardiovascular procedures, organ transplantation, orthopedic surgery, neurological surgery, and labor and delivery.
